Sinopharm Group Co. Ltd.
SHTDY · OTC
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $585 | $597 | $552 | $521 |
| % Growth | -2% | 8% | 6% | – |
| Cost of Goods Sold | $540 | $548 | $505 | $477 |
| Gross Profit | $44 | $49 | $47 | $44 |
| % Margin | 7.6% | 8.1% | 8.6% | 8.5% |
| R&D Expenses | $0 | $0 | $0 | $0 |
| G&A Expenses | $8 | $9 | $8 | $8 |
| SG&A Expenses | $26 | $26 | $25 | $23 |
| Sales & Mktg Exp. | $17 | $17 | $17 | $15 |
| Other Operating Expenses | $2 | $2 | $2 | $1 |
| Operating Expenses | $28 | $28 | $27 | $24 |
| Operating Income | $16 | $20 | $21 | $20 |
| % Margin | 2.8% | 3.4% | 3.7% | 3.8% |
| Other Income/Exp. Net | -$2 | -$1 | -$2 | -$3 |
| Pre-Tax Income | $14 | $20 | $19 | $17 |
| Tax Expense | $4 | $5 | $4 | $4 |
| Net Income | $7 | $9 | $9 | $8 |
| % Margin | 1.2% | 1.5% | 1.5% | 1.5% |
| EPS | 11.3 | 14.5 | 13.65 | 12.45 |
| % Growth | -22.1% | 6.2% | 9.6% | – |
| EPS Diluted | 11.3 | 14.5 | 13.65 | 12.45 |
| Weighted Avg Shares Out | 1 | 1 | 1 | 1 |
| Weighted Avg Shares Out Dil | 1 | 1 | 1 | 1 |
| Supplemental Information | – | – | – | – |
| Interest Income | $1 | $1 | $1 | $1 |
| Interest Expense | $3 | $3 | $4 | $4 |
| Depreciation & Amortization | $2 | $4 | $4 | $4 |
| EBITDA | $20 | $27 | $26 | $25 |
| % Margin | 3.5% | 4.5% | 4.8% | 4.7% |